Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AD/PD 2024 | The preventative potential of gamma frequency stimulation for preclinical Alzheimer’s disease

Diane Chan, MD, PhD, Massachusetts Institute of Technology, Cambridge, MA, provides a brief summary of ongoing studies of non-invasive gamma frequency stimulation, including a randomized control clinical trial underway in patients with preclinical or prodromal Alzheimer’s disease (AD). Alzheimer’s pathology is characterized by reduced fast brain oscillations in the gamma band, with this disruption observed in nascent stages of AD pathogenesis in human patients and mouse models. Audiovisual gamma stimulation utilizes light and sound stimulation to boost gamma oscillations. This study aims to evaluate the therapeutic potential of gamma frequency stimulation in patients with probable AD, and signals that novel neurostimulatory techniques may be employed to delay progression to dementia in the future. This interview took place at the AD/PD™ 2024 congress in Lisbon, Portugal.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.